Indivior PLC INVVY
Set alert
As of Jun 9, 10:23 AM ET
- Open
- 21.65
- Prev close
- 21.85
- Mkt cap
- 3.01B
- Vol
- 8.10K
- Avg vol
- 3.71K
- EPS
- -0.35
- P/E
- -62.42
More statistics
- Low
- 21.85
- High
- 21.85
- Earnings
- Jun 15, 2023
News
2 days ago globenewswire.com
Indivior Reports Third Quarter 2026 Financial Results
Q3'26 Total Net Revenue of $ 356 Million, Up 13% YoY Record Quarterly Total SUBLOCADE® Net Revenue of $ 267 Million in Q3'26, Up 22% YoY Record Quarterly Net Income of $ 137 Million and Record…
1 week ago globenewswire.com
Indivior to Report Third Quarter 2026 Financial Results
RICHMOND, Va., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its third quarter 2026 financial results on Thursday, October 29,…
1 month ago globenewswire.com
Addex Regains Rights to GABAB Positive Allosteric Modulator Portfolio from Indivior
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 25, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company developing novel small…
1 month ago globenewswire.com
Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend
RICHMOND, Va., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) (“Indivior”) today announced that its Board of Directors declared a special cash dividend (the "Special…
2 months ago businesswire.com
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV) and Supernus Pharmaceuticals, Inc. Upon closing…
2 months ago zacks.com
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026
INDV's proposed Supernus merger could broaden its CNS portfolio, cut costs and reduce reliance on Sublocade, but closing remains uncertain.
2 months ago defenseworld.net
Indivior (OTCMKTS:INVVY) Share Price Passes Below Two Hundred Day Moving Average – Should You Sell?
Shares of Indivior PLC (OTCMKTS:INVVY - Get Free Report) crossed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $21.85 and traded as low as…
2 months ago benzinga.com
Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Revenue
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) and Indivior Pharmaceuticals Inc. (NASDAQ:INDV) on Monday agreed to unite through a tax-free all-stock merger of equals, forming a central nervous system…
2 months ago businesswire.com
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Indivior Pharmaceuticals, Inc. (NASDAQ: INDV) and Supernus Pharmaceuticals, Inc. Upon closing…
2 months ago zacks.com
Indivior Pharmaceuticals Inc. (INDV) Q2 Earnings and Revenues Beat Estimates
Indivior Pharmaceuticals Inc. (INDV) came out with quarterly earnings of $1.15 per share, beating the Zacks Consensus Estimate of $0.97 per share. This compares to earnings of $0.51 per share a year…
2 months ago reuters.com
Supernus, Indivior merge to strengthen neuroscience drug portfolio
Supernus Pharmaceuticals and Indivior Pharmaceuticals said on Monday they had agreed to an all-stock merger that would create a company with about $2.2 billion in annual revenue and a portfolio of…
2 months ago globenewswire.com
Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
• Q2'26 Total Net Revenue of $ 343 Million, Up 14% YoY • Record Quarterly Total SUBLOCADE® Net Revenue of $ 253 Million in Q2'26, Up 21% YoY • Record Quarterly GAAP Net Income of $122 Million and…
2 months ago globenewswire.com
Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
ROCKVILLE, Md. and RICHMOND, Va., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) and Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that they have…
3 months ago globenewswire.com
Indivior to Report Second Quarter 2026 Financial Results and Host Webcast
RICHMOND, Va., July 23, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its second quarter 2026 financial results on Tuesday, August 4,…
4 months ago zacks.com
Indivior Pharmaceuticals Inc. (INDV) is on the Move, Here's Why the Trend Could be Sustainable
Indivior Pharmaceuticals Inc. (INDV) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks…
4 months ago zacks.com
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook article.
4 months ago zacks.com
Is Indivior Stock a Buy After Higher 2026 Guidance?
Indivior raised 2026 guidance after strong Q1 results, but investors are watching whether Sublocade growth and margin gains can sustain momentum.
5 months ago zacks.com
Bears are Losing Control Over Indivior Pharmaceuticals Inc. (INDV), Here's Why It's a 'Buy' Now
Indivior Pharmaceuticals Inc. (INDV) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate…
5 months ago globenewswire.com
Indivior to Participate in Upcoming Investor Conferences
RICHMOND, Va., May 14, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will participate in the following upcoming investor conferences: 2026 Jefferies…
5 months ago zacks.com
Indivior Pharmaceuticals Inc. (INDV) is a Great Momentum Stock: Should You Buy?
Does Indivior Pharmaceuticals Inc. (INDV) have what it takes to be a top stock pick for momentum investors? Let's find out.
-
6 years ago benzinga.com
Earnings Scheduled For July 30, 2020
Companies Reporting Before The Bell • Mastercard Inc. (NYSE:MA) is expected to report quarterly earnings at $1.16 per share on revenue of $3.23 billion. • Moody's Inc. (NYSE:MCO) is expected to…